Boston Scientific (NYSE:BSX) said today that it won CE Mark approval in the European Union for its Vercise Gevia deep-brain stimulation device for treating movement disorder symptoms.

Marlborough, Mass.-based Boston Scientific said the new system features programming software called the Vercise Neural Navigator 2 with Stimview, designed to allow physicians to see images of the stimulation field while the Vercise Gevia is configured. The MR-conditional, rechargeable system also has an estimated battery life of 25 years, the company said.

“Five years ago, Boston Scientific was the 1st to bring an 8-contact rechargeable platform offering 25 years of longevity, quickly followed by the introduction of the 1st directional lead powered by a small primary cell device,” neuromodulation president Maulik Nanavaty said in prepared remarks. “Today, we are thrilled to provide the 1st rechargeable, directional DBS system that is also full-body MRI-conditional and the 1st programming software with Stimview technology. Boston Scientific is dedicated to providing transformative technology to equip clinicians and improve the lives of patients.”

“The Gevia system addresses the needs of both patients and physicians with the latest advances in DBS therapy,” added Dr. Ludvic Zrinzo of London’s National Hospital for Neurology & Neurosurgery. “With the Gevia system, patients benefit from directional stimulation within a rechargeable system while maintaining the ability to have an MRI. This flexibility in DBS therapy is a clear step forward for patients.”

“I now have the potential to better define the settings that can help patients because I have the ability to visualize their stimulation field while I am programming,” said Dr. Patricia Limousin, also of the National Hospital for Neurology & Neurosurgery. “The Neural Navigator software brings together some of the most critical information I need to customize therapy for patients.”